Suzetrigine represents a groundbreaking advancement in acute pain management as the first FDA-approved selective Nav1.8 inhibitor. This comprehensive review synthesizes data from clinical trials, pharmacological studies, and prescribing information to evaluate... ...

请注册登录后继续浏览